Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
LogicBio Therapeutics, Inc. (LOGC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 03/04/2022 |
8-K
| Quarterly results |
| 11/15/2021 |
8-K
| Quarterly results |
| 05/10/2021 |
8-K
| Quarterly results |
| 03/15/2021 |
8-K
| Quarterly results |
| 11/09/2020 |
8-K
| Quarterly results |
| 08/10/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 03/16/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/13/2019 |
8-K
| Quarterly results |
| 05/14/2019 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 14, 2019 LOGICBIO THERAPEUTICS, INC. Delaware 001-38707 47-1514975 99 Erie St. Cambridge, MA 02139 : 245-0399 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exc...",
"LogicBio Reports First Quarter 2019 Financial Results and Provides Business Updates CAMBRIDGE, Mass., May 14, 2019 - LogicBio Therapeutics, Inc. , a genome editing company focused on developing medicines to durably treat rare diseases, today reported financial results and provided a corporate update for the first quarter ended March 31, 2019. “During the quarter, we continued to make progress advancing GeneRide TM , our proprietary promoterless, nuclease-free genome editing platform, and built our team with several experienced hires.” said Fred Chereau, CEO of LogicBio. “In April, our lead candidate, LB-001, received orphan drug designation from the U.S. Food and Drug Administration for the treatment of methylmalonic acidemia , and we are continuing to work towards an Investigational New D..." |
|
| 04/01/2019 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 1, 2019 LOGICBIO THERAPEUTICS, INC. Delaware 001-38707 47-1514975 99 Erie St. Cambridge, MA 02139 : 245-0399 610 Main Street, 3rd Floor Cambridge, MA 02139 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pur...",
"LogicBio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates CAMBRIDGE, Mass., April 1, 2019 - LogicBio Therapeutics, Inc. , a genome editing company focused on developing medicines to durably treat rare diseases, today reported financial results and provided a corporate update for the fourth quarter and full year ended December 31, 2018. “In 2018 we made steady progress advancing GeneRide ™ , our proprietary promoterless, nuclease-free genome editing platform,” said Fred Chereau, CEO of LogicBio. “This year, we intend to file an Investigational New Drug application for our lead candidate, LB-001, in methylmalonic acidemia. We will also continue to build out our team to expand our CMC capacity and analytical development capabilities as we advance our p..." |
|
| 12/03/2018 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 3, 2018 LOGICBIO THERAPEUTICS, INC. Delaware 001-38707 47-1514975 610 Main Street, 3rd Floor Cambridge, MA 02139 : 245-0399 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule ...",
"LogicBio Reports Third Quarter 2018 Financial Results CAMBRIDGE, Mass., Dec. 3, 2018 - LogicBio Therapeutics, Inc. , a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, today reported financial results and provided a corporate update for the third quarter ended September 30, 2018. “Following our successful initial public offering in October, we believe we are in a strong financial position to continue developing our proprietary GeneRide TM technology platform with the potential to durably treat rare disease in pediatric patients. We are committed to building a world-class team and a broad pipeline of product candidates to capture the full value of GeneRide, beginning with LB-001 for the treatment of methyl..." |
|
|
|